Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "TULIP Trial - Trastuzumab Duocarmazine vs. Physician's Choice Therapy in Pre-Treated HER2+ mBC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Philippe Aftimos
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Philippe Aftimos
Login to view comments.
Click here to Login
Breast